Patents Assigned to The United States of America as represented by the Secretary, Department of Health and Human Services
  • ANTIBACTERIAL AND ANTIFUNGAL POLYKETIDES FROM ENVIRONMENTAL AMYCOLATOPSIS SPP
    Publication number: 20230106760
    Abstract: Disclosed are compounds represented by the formula:(I), wherein R is as defined herein, and pharmaceutically acceptable salts thereof. Also disclosed are a method of treating a subject in need of treatment for a bacterial infection or a fungal infection, which includes administering to the subject an effective amount of one of the compounds or salts thereof. Further disclosed is a process for producing the compounds and salts thereof.
    Type: Application
    Filed: March 16, 2021
    Publication date: April 6, 2023
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Carole A. Bewley Clore, Hongbing Liu, Shannon I. Ohlemacher
  • RP2 and RPGR vectors for treating X-linked retinitis pigmentosa
    Patent number: 11617801
    Abstract: Disclosed are adeno-associated virus (AAV) vectors comprising a nucleotide sequence encoding RP2 or RPGR-ORF15 and related pharmaceutical compositions. Also disclosed are methods of treating or preventing X-linked retinitis pigmentosa, increasing photoreceptor number in a retina of a mammal, and increasing visual acuity of a mammal using the vectors and pharmaceutical compositions.
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: April 4, 2023
    Assignee: The United States of America,as represented by the Secretary, Department of Health and Human Services
    Inventors: Zhijian Wu, Anand Swaroop, Suja Hiriyanna, Tiansen Li
  • Crystal forms and methods of synthesis of (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine
    Patent number: 11613514
    Abstract: The disclosure provides a method for synthesizing free base forms of (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hydroxynorketamine. In an embodiment synthesis of (2R,6R)-hydroxynorketamine (HNK) includes preparation of (R)-norketamine via chiral resolution from racemic norketamine via a chiral resolution with L-pyroglutamic acid. The disclosure also provided crystal forms of the corresponding (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hydroxynorketamine hydrochloride salts.
    Type: Grant
    Filed: January 22, 2021
    Date of Patent: March 28, 2023
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Craig Thomas, Carlos Zarate, Ruin Moaddel, Todd Gould, Panos Zanos, Patrick Morris
  • Radioactive source calibration
    Patent number: 11614548
    Abstract: Methods and apparatus for calibrating radioactive sources are described. An array of scintillation detectors form a receptacle within which a sample or sample container can be retained by a holder. The scintillation detectors are coupled via light transducers such as photomultiplier tubes (PMTs) to independent electronic counters. Coincidence processing of time-tagged events yields a correlated event rate. One or more corrections can be applied as needed, for background counts, deadtime, or random coincidences. Voltage tuning of PMTs yields improved reproducibility. Variations are disclosed. 1% accuracy has been demonstrated over a range of 10 kBq-3 MBq, covering a gap in the capabilities of conventional technology.
    Type: Grant
    Filed: May 7, 2021
    Date of Patent: March 28, 2023
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventor: Stephen S. Adler
  • T CELL RECEPTORS RECOGNIZING MHC CLASS II-RESTRICTED MAGE-A3
    Publication number: 20230089465
    Abstract: The invention provides an isolated or purified T-cell receptor (TCR) having antigenic specificity for MHC Class II-restricted MAGE-A3. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a mammal are further provided by the invention.
    Type: Application
    Filed: September 28, 2022
    Publication date: March 23, 2023
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Paul F. Robbins, Steven A. Rosenberg, Xin Yao
  • HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION
    Publication number: 20230082787
    Abstract: Disclosed are isolated or purified T cell receptors (TCRs), wherein the TCRs have antigenic specificity for a mutated RAS amino acid sequence presented by a human leukocyte antigen (HLA) Class I molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided.
    Type: Application
    Filed: February 12, 2021
    Publication date: March 16, 2023
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Noam Levin, Maria R. Parkhurst, Frank J. Lowery, III, Steven A. Rosenberg
  • HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION
    Publication number: 20230080742
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated human RAS amino acid sequence with a substitution of glycine at position 12 with aspartic acid presented by a human leukocyte antigen (HLA) Class I molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Application
    Filed: February 12, 2021
    Publication date: March 16, 2023
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Noam Levin, Rami Yoseph, Biman Paria, Steven A. Rosenberg
  • HIV-1 Env fusion peptide immunogens and their use
    Patent number: 11602559
    Abstract: Embodiments of immunogens based on the HIV-1 Env fusion peptide and methods of their use and production are disclosed. Nucleic acid molecules encoding the immunogens are also provided. In several embodiments, the immunogens can be used to generate an immune response to HIV-1 Env in a subject, for example, to treat or prevent an HIV-1 infection in the subject.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: March 14, 2023
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter Kwong, Rui Kong, Tongqing Zhou, John Mascola, Kai Xu, Cheng Cheng, Gwo-Yu Chuang, Kevin Liu, Baoshan Zhang, Li Ou, Wing-Pui Kong
  • N-(3-AMINO-3-OXOPROPYL)-2-[(1-METHYL-4-NITRO-1H-IMIDAZOL-5-YL)THIO]BENZAMIDE AND ITS USE FOR TREATING HIV INFECTION
    Publication number: 20230069100
    Abstract: Disclosed is a compound of formula (I): for treating or preventing a human immunodeficiency virus (HIV) infection in a mammal, for inhibiting or preventing maturation of an immature human immunodeficiency virus (HIV) to a mature HIV, and for preventing or inhibiting a human immunodeficiency virus (HIV) infection in a mammal having at least one HIV viral particle on a surface thereof.
    Type: Application
    Filed: December 17, 2020
    Publication date: March 2, 2023
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Daniel H. Appella, Herman Nikolayevskiy, Marco Robello, Michael T. Scerba
  • Recombinant human/bovine parainfluenza virus 1 (HPIV1) expressing a chimeric RSV/HPIV1 F protein and uses thereof
    Patent number: 11591372
    Abstract: Recombinant paramyxoviruses including a viral genome encoding a heterologous gene are provided. In several embodiments, the recombinant paramyxovirus is a recombinant parainfluenza virus, such as a recombinant PIV3 including a viral genome encoding a heterologous respiratory syncytial virus F ectodomain linked to the transmembrane domain and the cytoplasmic tail of the F protein from the PIV3. Nucleic acid molecules including the genome of a recombinant paramyxoviruses are also provided. The recombinant viruses may advantageously be used in vaccine formulations, such as for vaccines against parainfluenza virus and respiratory syncytial virus.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: February 28, 2023
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter Collins, Bo Liang, Shirin Munir, Anne Schaap Nutt, Ursula Buchholz, Natalie Mackow, Peter Kwong, Barney Graham, Jason McLellan
  • Heterocyclic P2Yreceptor antagonists
    Patent number: 11584736
    Abstract: Disclosed are compounds of formulas (I)-(IX) for treating or preventing a disease or disorder responsive to antagonism of a P2Y14R receptor agonist in a mammal in need thereof, wherein R1-R8, X, Y, Z, X?, Y?, Z?, and A are as defined herein, that are useful in treating an inflammatory such as asthma, cystic fibrosis, and sterile inflammation of the kidney.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: February 21, 2023
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Kenneth A. Jacobson, Jinha Yu, Antonella Ciancetta, Zhiwei Wen, Young-Hwan Jung
  • Modified cells and methods of therapy
    Patent number: 11583556
    Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: February 21, 2023
    Assignees: Regents of the University of Minnesota, Intima Bioscience, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Branden Moriarity, Beau Webber, Modassir Choudhry, R. Scott McIvor, David Largaespada, Steven A. Rosenberg, Douglas C. Palmer, Nicholas P. Restifo
  • Method and system of building hospital-scale chest X-ray database for entity extraction and weakly-supervised classification and localization of common thorax diseases
    Patent number: 11583239
    Abstract: A new chest X-ray database, referred to as “ChestX-ray8”, is disclosed herein, which comprises over 100,000 frontal view X-ray images of over 32,000 unique patients with the text-mined eight disease image labels (where each image can have multi-labels), from the associated radiological reports using natural language processing. We demonstrate that these commonly occurring thoracic diseases can be detected and spatially-located via a unified weakly supervised multi-label image classification and disease localization framework, which is validated using our disclosed dataset.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: February 21, 2023
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Service
    Inventors: Xiaosong Wang, Yifan Peng, Le Lu, Zhiyong Lu, Ronald M. Summers
  • Nucleic acids encoding Zika virus-like particles and their use in Zika virus vaccines and diagnostic assays
    Patent number: 11578103
    Abstract: Transcriptional units encoding Zika virus (ZIKV) premembrane (prM) and envelope (E) proteins, which upon translation form Zika virus-like particles (VLPs), are described. Use of the transcriptional units and VLPs in three different ZIKV vaccine platforms is described. Immunoassay-based detection methods using ZIKV VLPs are described for the diagnosis of ZIKV infection.
    Type: Grant
    Filed: February 5, 2021
    Date of Patent: February 14, 2023
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Gwong-Jen J. Chang, Brent S. Davis
  • Method for subtyping lymphoma types by means of expression profiling
    Patent number: 11574704
    Abstract: The invention is directed to methods for selecting a treatment option for an activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) subject, a germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL) subject, a primary mediastinal B cell lymphoma (PMBL) subject, a Burkitt lymphoma (BL) subject, or a mantle cell lymphoma (MCL) subject by analyzing digital gene expression data obtained from the subject, e.g., from a biopsy sample.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: February 7, 2023
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, British Columbia Cancer Agency Branch, Arizona Board of Regents on Behalf of the University of Arizona, Universitat de Barcelona, Hospital Clinic de Barcelona
    Inventors: Louis M. Staudt, George W. Wright, David William Scott, Joseph M. Connors, Randy D. Gascoyne, Lisa Rimsza, Elias Campo Guerri, Raymond Tubbs, Timothy C. Greiner, James Robert Cook, Kai Fu, Paul Michael Williams, Chih-Jian Lih, Elaine S. Jaffe, Rita M. Braziel, Andreas Rosenwald, Erlend B. Smeland, Wing C. Chan, German Ott, Jan Delabie, Dennis Weisenburger
  • METHODS OF PRODUCING T CELL POPULATIONS USING INDUCED PLURIPOTENT STEM CELLS
    Publication number: 20230036952
    Abstract: Provided are methods of producing an isolated population of T cells for adoptive cell therapy. Also provided are related isolated populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer, infections, and autoimmune conditions in a patient.
    Type: Application
    Filed: January 7, 2021
    Publication date: February 2, 2023
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Meghan L. Good, Rafiqul SM Islam, Naritaka Tamaoki, Raul E. Vizcardo, Nicholas P. Restifo
  • ANTIBODIES TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF
    Publication number: 20230029635
    Abstract: Disclosed are anti-C3d antibodies or fragments thereof. Also disclosed are methods of killing cancer cells, methods of preparing anti-C3d antibodies, and pharmaceutical compositions.
    Type: Application
    Filed: December 8, 2020
    Publication date: February 2, 2023
    Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, The Scripps Research Institute
    Inventors: Adrian Wiestner, Christoph Rader, Haiyong Peng, Sivasubramanian Baskar, Erika Gaglione
  • HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS
    Publication number: 20230026180
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated RAS amino acid sequence presented by a human leukocyte antigen (HLA) Class I molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Application
    Filed: September 12, 2022
    Publication date: January 26, 2023
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Rami Yoseph, Yong-Chen Lu, Gal Cafri, Steven A. Rosenberg
  • Tumor ablation training system
    Patent number: 11562665
    Abstract: A training system and method includes a subject phantom (102) capable of being visualized on a display (120). A spatial tracking system (104) is configured to track an interventional instrument (108) in subject phantom space. A simulation system (110) is configured to generate a simulated abnormality in the phantom space and to simulate interactions with the simulated abnormality to provide feedback and evaluation information to a user for training the user in an associated procedure related to the abnormality.
    Type: Grant
    Filed: May 14, 2010
    Date of Patent: January 24, 2023
    Assignees: KONINKLIJKE PHILIPS N.V., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Jochen Kruecker, Sheng Xu, Sandeep Dalal, Bradford Johns Wood
  • MULTI-DIMENSIONAL SPECTROSCOPIC NMR AND MRI USING MARGINAL DISTRIBUTIONS
    Publication number: 20230019387
    Abstract: Multi-dimensional spectra associated with a specimen are reconstructed using lower dimensional spectra as constraints. For example, a two-dimensional spectrum associated with diffusivity and spin-lattice relaxation time is obtained using one-dimensional spectra associated with diffusivity and spin-lattice relaxation time, respectively, as constraints. Data for a full two dimensional spectrum are not acquired, leading to significantly reduced data acquisition times.
    Type: Application
    Filed: July 13, 2022
    Publication date: January 19, 2023
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Peter J. Basser, Dan H. Benjamini